A phase 1 clinical trial for cancer/solid tumors
Latest Information Update: 20 Jul 2020
At a glance
- Drugs IGF 1R antisense therapy (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Imvax
Most Recent Events
- 16 Jul 2020 According to a Imvax media release, this study is expected to begin during 2021.
- 12 Sep 2019 New trial record